CAS 32302-76-4: glycyl-L-prolyl-L-glutamic acid

Glypromate

Applications GLY-PRO-GLU (cas# 32302-76-4) is a useful research chemical.

IGF-I (1-3) H-Gly-Pro-Glu-OH is a synthetic peptide that has been shown to be effective in treating neuronal death caused by glutamate. It binds to calcium ions and inhibits the activity of gamma-aminobutyric acid, which is an inhibitory neurotransmitter. IGF-I (1-3) H-Gly-Pro-Glu-OH also blocks fatty acid synthesis, leading to necrotic cell death. In vitro assays have shown that this drug can protect against blood group O erythrocytes from pyridoxal phosphate oxidation and protocatechuic acid binding. This drug has also been shown to increase locomotor activity in mice, as well as improve motor function in rats with experimental stroke. IGF-I (1-3) H-Gly-Pro-Glu-OH is synthesized using a polymerase chain reaction technique and consists of amino acids 1 through 3 of

This N-terminal tripeptide of IGF-I facilitated the in vitro release of acetylcholine with a several hundredfold higher potency (10⁻¹⁰ - 10⁻⁶ M) than intact IGF-I (4 · 10⁻⁸ M), whereas truncated IGF-I lacking the tripeptide GPE, did not show any significant effect. This raises the possibility that GPE may be the active site of IGF-I. - Although the precise mode of action of GPE is still unknown, another study suggests that local administration of GPE is neuroprotective after brain HI injury via glial cells. In addition, systemic administration of GPE showed a more widespread neuroprotective effect. Therefore, GPE may represent a complementary pathway for central and systemic IGF-1’s antiapoptotic effects.

Glypromate (Gly-Pro-Glu) is a neuroprotective agent, is a weak NMDA receptor agonist